Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05113693
Other study ID # A98_05BE2118
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date November 25, 2021
Est. completion date December 10, 2021

Study information

Verified date June 2023
Source Chong Kun Dang Pharmaceutical
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Objective - Evaluation of the pharmacokinetic properties and safety of CKD-393 0.25/50/750 mg oral administration in healthy adults under fed condition.


Recruitment information / eligibility

Status Completed
Enrollment 33
Est. completion date December 10, 2021
Est. primary completion date December 6, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years to 54 Years
Eligibility Inclusion Criteria: 1. Healthy adult volunteers aged 19 = ~ < 55-year-old. 2. Weight =55kg (man) or 45kg (woman), with calculated body mass index (BMI) of 17.5 = ~ < 30.5 kg/m2. 3. Those who have no congenital diseases or chronic diseases within 3 years and have no abnormal symptoms or findings. 4. Those who are eligible for clinical trials based on laboratory (hematology, blood chemistry, serology, urology) and 12-lead ECG results at screening. 5. Those who voluntarily decide to participate and agree to comply with the cautions after fully understand the detailed description of this clinical trial. 6. Those who agree to contraception until the 1 month after last administration of clinical trial drugs. 7. Those who have the ability and willingness to participate during the entire clinical trail. Exclusion Criteria: 1. Those who have clinically significant disease or medical history of heart failure, Hepatopathy, Type 1 Diabetes, Diabetic ketoacidosis, Edema, Renal dysfunction, galactose intolerance, glucose-galactose malabsorption. And Those who receive intravenous administration of radioactive iodine contrast agents (for intravenous urography, venous cholangiography, angiography, computed tomography using contrast agents, etc.) during clinical trial. 2. Those who have past medical history of gastrointestinal disorder (Crohn's disease, ulcerative colitis, etc. except simple appendectomy or hernia surgery), which affect the absorption of investigational drug. 3. Those who have the test results written below - AST, ALT > 2 times higher than upper normal level 4. Those who exceeding an alcohol consumption criteria(210g/week) within 6 months before the first administration of investigational drug. - Beer 1 glass(250ml, Alcohol contents 5%) = 10g - Soju 1 glass(50ml, Alcohol contents 20%) = 8g - Wine 1 glass(125ml, Alcohol contents 12%) = 12g 5. Those who exceeding smoking criteria(20 cigarettes/day) within 6 months before the first administration of investigational drug. 6. Those who received investigational durg by participating in other clinical trial within 6 months before the first administration of investigational drug. 7. Those who have vital sign written below - systolic blood pressure =140 mmHg or < 90 mmHg - diastolic blood pressure = 90 mmHg or < 60 mmHg 8. Those who have a drug or alcohol abuse history within 1 year before the first administration of investigational drug. 9. Those who take barbiturate and related (causing induction or inhibition. of metabolism) drug within 30 days before the first administration of investigational drug. 10. Those who received Ethical-the-counter (ETC) drugs or Over-the-counter (OTC) drugs within 10 days before the first administration of investigational drug. 11. Those who donated whole blood within 2 months or apheresis within 1 month before the first administration of investigational drug. 12. Those who severe acute/chronic medical or mental condition which can increase the safety risk by administration of investigational drug. 13. Those who have history of hypersensitivity to active pharmaceutical ingredient or additives. 14. Those who are pregnant or breastfeeding. 15. Those who can't ingest a high fat diet. 16. Those who are deemed inappropriate to participate in clinical trial by investigators.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
CKD-393
QD, PO
CKD-501, D759, H053
QD, PO

Locations

Country Name City State
Korea, Republic of Chonbuk National University Hospital Jeonju

Sponsors (1)

Lead Sponsor Collaborator
Chong Kun Dang Pharmaceutical

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary AUCt of CKD-501, D759, H053 AUCt: Area under the concentration-time curve from time zero to time Pre-dose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hour
Primary Cmax of CKD-501, D759, H053 Cmax: Maximum plasma concentration of the drug Pre-dose(0 hour), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hour
See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT05979779 - Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Obese Subjects With Type 2 Diabetes at Risk of Nonalcoholic Steatohepatitis Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3